Evidence map›Paper›PMID 29271489›Full record

ArticleJournal of cellular physiology2019

Differential mechanisms of adenosine- and ATPγS-induced microvascular endothelial barrier strengthening.

Róbert Bátori, Sanjiv Kumar, Zsuzsanna Bordán, Mary Cherian-Shaw, Anita Kovács-Kása, Justin A MacDonald, David J R Fulton, Ferenc Erdődi, Alexander D Verin

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.International journal of environmental research and public health · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Róbert BátoriVascular Biology Center, Augusta University, Augusta, Georgia.ORCID 0000-0002-1400-6732
Sanjiv KumarVascular Biology Center, Augusta University, Augusta, Georgia.
Zsuzsanna BordánVascular Biology Center, Augusta University, Augusta, Georgia.
Mary Cherian-ShawVascular Biology Center, Augusta University, Augusta, Georgia.
Anita Kovács-KásaVascular Biology Center, Augusta University, Augusta, Georgia.ORCID 0000-0001-7244-5517
Justin A MacDonaldDepartment of Biochemistry & Molecular Biology, Smooth Muscle Research Group, University of Calgary, Calgary, Alberta, Canada.
David J R FultonVascular Biology Center, Augusta University, Augusta, Georgia.
Ferenc ErdődiDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Alexander D VerinVascular Biology Center, Augusta University, Augusta, Georgia.
Augusta University Health · USAugusta University · USUniversity of Calgary · CAUniversity of Debrecen · HU

Funding

Therapeutic Mechanisms of RhoA Inhibition In Acute Lung InjuryP01HL101902 · NHLBI · AUGUSTA UNIVERSITY · PI BLACK, STEPHEN M · 2011 to 2016
$11.2M
CIHR MOP-133494NHLBI NIH HHS P01 HL101902
6 · The paper itself

Abstract

Maintenance of the endothelial cell (EC) barrier is critical to vascular homeostasis and a loss of barrier integrity results in increased vascular permeability. While the mechanisms that govern increased EC permeability have been under intense investigation over the past several decades, the processes regulating the preservation/restoration of the EC barrier remain poorly understood. Herein we show that the extracellular purines, adenosine (Ado) and adenosine 5'-[γ-thio]-triphosphate (ATPγS) can strengthen the barrier function of human lung microvascular EC (HLMVEC). This ability involves protein kinase A (PKA) activation and decreases in myosin light chain 20 (MLC20) phosphorylation secondary to the involvement of MLC phosphatase (MLCP). In contrast to Ado, ATPγS-induced PKA activation is accompanied by a modest, but significant decrease in cyclic adenosine monophosphate (cAMP) levels supporting the existence of an unconventional cAMP-independent pathway of PKA activation. Furthermore, ATPγS-induced EC barrier strengthening does not involve the Rap guanine nucleotide exchange factor 3 (EPAC1) which is directly activated by cAMP but is instead dependent upon PKA-anchor protein 2 (AKAP2) expression. We also found that AKAP2 can directly interact with the myosin phosphatase-targeting protein MYPT1 and that depletion of AKAP2 abolished ATPγS-induced increases in transendothelial electrical resistance. Ado-induced strengthening of the HLMVEC barrier required the coordinated activation of PKA and EPAC1 in a cAMP-dependent manner. In summary, ATPγS-induced enhancement of the EC barrier is EPAC1-independent and is instead mediated by activation of PKA which is then guided by AKAP2, in a cAMP-independent mechanism, to activate MLCP which dephosphorylates MLC20 resulting in reduced EC contraction and preservation.

Indexed as

Adenosine TriphosphateA Kinase Anchor ProteinsCapillary PermeabilityCyclic AMPCyclic AMP-Dependent Protein KinasesElectric ImpedanceGuanine Nucleotide Exchange FactorsHEK293 CellsHumansMembrane ProteinsMicrovesselsMyosin-Light-Chain PhosphataseMyosin Light ChainsPhosphorylationPurinergic P1 Receptor AgonistsReceptors, Purinergic P1adenosine 5'-O-(3-thiotriphosphate)Adenosine TriphosphateAKAP2 protein, humanA Kinase Anchor ProteinsCyclic AMPCyclic AMP-Dependent Protein KinasesGuanine Nucleotide Exchange FactorsMembrane ProteinsMyosin-Light-Chain PhosphataseMyosin Light ChainsPPP1R12A protein, humanPurinergic P1 Receptor AgonistsRAPGEF3 protein, humanReceptors, Purinergic P1adenosineATPγSendothelial barrier protectionmyosin light chainPKA

Identifiers

PMID29271489
PMCPMC7273968
OpenAlexW2780603443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.